Open AccessClinical study of Repatha: it does not affect patients’ cognitive function and significantly reduce blood lipid and prevent coronary atherosclerosis
Author(s) -
Yongzhe Li
Publication year - 2022
Publication title -
highlights in science, engineering and technology
Language(s) - English
Resource type - Journals
ISSN - 2791-0210
DOI - 10.54097/hset.v8i.1180
Subject(s) - medicine , hyperlipidemia , myocardial infarction , clinical trial , disease , blood lipids , evolocumab , coronary heart disease , adverse effect , cardiology , cholesterol , diabetes mellitus , lipoprotein , endocrinology , apolipoprotein a1